Caricamento...

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis

Elagolix is a novel, oral gonadotropin‐releasing hormone receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids. Consistent with its mechanism of action, elagolix exhibited dose‐dependent...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Transl Sci
Autori principali: Stodtmann, Sven, Nader, Ahmed, Polepally, Akshanth R., Suleiman, Ahmed A., Winzenborg, Insa, Noertersheuser, Peter, Ng, Juki, Mostafa, Nael M., Shebley, Mohamad
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2021
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8301592/
https://ncbi.nlm.nih.gov/pubmed/33963686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.13040
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !